AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project

Recruitingn/aAges 20 Years - 29 YearsAllAssistance Publique Hopitaux De Marseille
💬

In plain words

What the trial is, and whether it could suit you

Haemophilia is a rare genetic disorder which, in its severe form and in the absence of treatment, can be life-threatening. Since the 1960s and the introduction of coagulation factor concentrates, the life expectancy of people with haemophilia has increased rapidly. Today, for most affected individuals, the disease is experienced as a chronic condition. The transition process enabling adolescents and young adults (AYA) with a chronic disease to move into adult life can be complex, as they must face all the changes experienced by AYA in general, combined with issues related to their chronic condition and its management. A successful transition involves a transfer of responsibility from parents to AYA regarding the management of their health condition, as well as the acquisition by AYA of knowledge, skills and autonomy. A difficult transition may lead to decreased adherence to follow-up o

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Young adults who participated in the TRANSHEMO project during adolescence and who are currently aged 20-29 years; * Young adults with severe haemophilia (haemophilia A or B); * Young adults registered in the FranceCoag registry; * Young adults who have received the participant information sheet for the TRANSHEMO 2 project; * Young adults who did not object to participation in the present study. Exclusion Criteria: * patients with comprehension difficulties; * patients who are unable to read and/or write; * patients who express opposition to participation in this study.
💊

What it tests

  • questionnaires
📍

Where

25 sites
CHU La Reunion
Saint-Denis, France
CH Annecy - St Julien
Annecy, France
Chu de Bordeaux
Bordeaux, France
Chu de Caen
Caen, France
Centre hospitalier Métropole Savoie
Chambéry, France
CHU Clermont-Ferrand
Clermont-Ferrand, France
Chu de Dijon
Dijon, France
Chu de Grenoble
Grenoble, France

…and 17 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy